{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "ARHS", "name": "Arhaus, Inc.", "url": "https://frontierpicks.com/dossiers/ARHS/", "json_url": "https://frontierpicks.com/dossiers/ARHS.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a7", "n": 7 }, "current_thesis": "Arhaus's order-recovery thesis requires Q3 2026 delivered-sales growth above Q2's 4.0% and a weekly close above the lost $9.00 market shelf. A weekly close below $8.00 invalidates the case.", "invalidation_trigger": "A weekly close below $8.00 invalidates the remaining recovery structure; Q3 2026 comparable delivered-sales growth at or below negative 1%, the floor of management's 2026-08-06 guidance, separately contradicts the order-conversion thesis.", "catalyst_date": "2026-09-15", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "oil-energy-geopolitical" ], "tags": [], "sources": [], "notes": [ "Dual-class structure: Class B carries ten votes per share and the founder block holds the controlling vote, so Class A float is far smaller than shares outstanding.", "Q2 2026 GAAP margins include a $23.8M IEEPA tariff refund booked in COGS; headline gross margin is not comparable year over year.", "Delivered revenue lags written orders by roughly a quarter on made-to-order lead times; client deposits on the balance sheet are the forward order book.", "Calendar fiscal year. Q3 results are normally released in early November, with the date announced about a week ahead.", "The 2026-09-09 Barclays and 2026-09-15 Piper Sandler appearances are private investor meetings and will not be webcast, so neither produces a public disclosure." ], "body_markdown": "## Current Thesis\n\nArhaus's order-recovery thesis requires faster delivered-sales growth at Q3 results and recovery of the lost $9.00 market shelf before a weekly close below $8.00 invalidates it. The 2026-09-11 adjusted close was $8.10, below the $8.98 close recorded on 2026-08-28. The operating premise remains the gap between Q2 2026 comparable written-sales growth of 12.5% and delivered-sales growth of 4.0%, reported on 2026-08-06. Conversion of those orders remains an inference, not a reported result. [Arhaus Q2 results](https://ir.arhaus.com/news-releases/news-release-details/arhaus-reports-second-quarter-2026-financial-results).\n\nThe narrative is maturing — the order inflection has been public since 2026-08-06, while the supplied adjusted closes show further deterioration through 2026-09-11. The September refresh also changes the insider evidence: a 2026-09-10 filing reports a director sale, superseding the earlier absence-of-selling observation. Neither that transaction nor the price decline establishes weaker customer demand. [Director Form 4](https://ir.arhaus.com/node/10161/html).\n\n## Bull Case\n\n- **Orders outpaced delivered sales.** Arhaus reported Q2 2026 comparable written-sales growth of 12.5% against delivered-sales growth of 4.0% on 2026-08-06. The recovery case requires subsequent conversion; Q3 delivered growth at or below the company's negative 1% guidance floor would contradict it. [Q2 results](https://ir.arhaus.com/news-releases/news-release-details/arhaus-reports-second-quarter-2026-financial-results).\n- **Liquidity accompanies the order recovery.** Arhaus reported $226 million in cash and no long-term debt at 2026-06-30. These are balance-sheet facts, not evidence that the market decline has ended. [Q2 results](https://ir.arhaus.com/news-releases/news-release-details/arhaus-reports-second-quarter-2026-financial-results).\n\n## Bear Case\n\n- **Tariff recoveries complicate profit comparisons.** Q2 2026 gross profit included a $23.8 million tariff-recovery benefit. The 2026-08-06 release also identified $14.0 million primarily related to inventory-cost reductions at 2026-06-30; Q3 cannot be assumed free of recovery effects. [Q2 results](https://ir.arhaus.com/news-releases/news-release-details/arhaus-reports-second-quarter-2026-financial-results).\n- **Guidance permits weaker delivered demand.** On 2026-08-06, management forecast Q3 revenue of $355–375 million and comparable delivered-sales growth of negative 1% to positive 5%. The forecast allows the written-order improvement to coexist with a delivered-sales decline. [Q2 results](https://ir.arhaus.com/news-releases/news-release-details/arhaus-reports-second-quarter-2026-financial-results).\n\n## Setup & Price Structure\n\nThe supplied split- and dividend-adjusted series places the 2026-09-11 close at $8.10, with a three-month price increase of 13.0% and a 14-period relative strength index (RSI) of 26.9. The shares stood 28.4% below the supplied 52-week high of $11.31. These observations document price weakness; they do not establish a reversal. No moving-average value or participation series is available to substantiate a rising-average or expanding-demand claim.\n\nThe $9.00 shelf identified in the August coverage remains unrecovered at the 2026-09-11 close. A weekly close above $9.00 would satisfy the price component of the recovery case; a weekly close below $8.00 would end it. The September reference close leaves the case unconfirmed and supports low conviction.\n\nDirector Alton F. Doody III reported selling 3,500 Class A shares on 2026-09-08 at $8.47 in his 2026-09-10 Form 4. This is an observable insider transaction, not evidence of issuance or broad insider distribution. The sample is too small to support a crowding claim, and no dated retail-sentiment or short-interest series establishes one. [Director Form 4](https://ir.arhaus.com/node/10161/html).\n\n## Catalyst Calendar (next 30 days)\n\nAs of 2026-09-13, the company's event calendar does not list a Q3 2026 earnings date. The previously scheduled 2026-09-09 Barclays appearance is elapsed. No confirmed Q3 reporting date is available for publication. [Arhaus events](https://ir.arhaus.com/news-events/events), [conference announcement](https://arhaus.gcs-web.com/news-releases/news-release-details/arhaus-announces-participation-upcoming-investor-conferences).\n\n## Elapsed catalysts\n\n- **2026-09-15 — Piper Sandler Growth Frontiers Conference.** Arhaus's 2026-08-12 announcement schedules management investor meetings in Nashville and states that they will not be webcast. The appearance does not itself provide a public operating update; only a subsequent disclosure could resolve the conversion question. [Conference announcement](https://arhaus.gcs-web.com/news-releases/news-release-details/arhaus-announces-participation-upcoming-investor-conferences). *(passed 5d ago)*\n\n## What Would Change Our Mind\n\nLoss of the remaining $8.00 threshold would break the residual recovery structure: a weekly close below $8.00 invalidates the thesis, retaining the condition published on 2026-08-30. Q3 comparable delivered-sales growth at or below negative 1%, the floor of management's 2026-08-06 guidance, would separately contradict the conversion case.\n\nFor the thesis to play out, Q3 comparable delivered-sales growth must exceed Q2 2026's reported 4.0%, and the market must record a weekly close above the lost $9.00 shelf before the $8.00 invalidation fires. These are research conditions, not reported outcomes.\n\n## Correlation Notes\n\nThis remains a single-company order-conversion case. Arhaus's 2026-08-06 outlook explicitly cited consumer uncertainty and the timing of written-order conversion, supporting those exposures as relevant operating variables. The available evidence contains no matched peer-return or housing-data series; it cannot establish a measured correlation or a category-wide recovery. [Q2 outlook](https://ir.arhaus.com/news-releases/news-release-details/arhaus-reports-second-quarter-2026-financial-results).", "first_seen": "2026-08-19", "last_analyzed": "2026-09-13T00:52:03+00:00", "last_synthesized": "2026-09-13", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }